Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Opus Genetics, Inc. (IRD)

Opus Genetics revises OPGx-BEST1 Cohort 1 data, corrects visual acuity error

Mixed Impact 2 of 5 other Written later

Opus Genetics filed a revised data presentation on September 11, 2026, correcting an error in the Cohort 1 results of its OPGx-BEST1 gene therapy trial that it presented at its September 9, 2026 investor conference. The error was in converting logMAR visual acuity to ETDRS letters on Slide 15, and the company calls it immaterial. The filing also lists each participant's three-month letter change, and two participants show losses in the treated eye, so shareholders may want to review the corrected figures.

Key points

  • Slide 15, which charts mean best-corrected visual acuity from baseline through 3 months in Cohort 1, was corrected for a logMAR-to-ETDRS translation error.
  • Corrected three-month changes in the treated eye: 101-101 up 12 letters, 101-104 up 1, 102-101 down 10, 102-102 up 2, 101-106 up 6.
  • Corrected three-month changes in the fellow eye: 101-101 up 4 letters, 101-104 down 7, 102-101 down 8, 102-102 down 5, 101-106 up 2.
  • Microperimetry grid images for baseline and 3 months were added to the appendix; the original presentation was furnished on September 9, 2026.

The filing

CompanyOpus Genetics, Inc. (IRD)
Form8-K, current report
Filed with the SECSep 11, 2026, 7:48 AM ET
Accession number0001140361-26-036277

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.